keyword
MENU ▼
Read by QxMD icon Read
search

CSF and Alzheimer

keyword
https://www.readbyqxmd.com/read/28320113/alzheimer-s-disease-elevated-pigment-epithelium-derived-factor-in-the-cerebrospinal-fluid-is-mostly-of-systemic-origin
#1
Veronika Lang, Marietta Zille, Carmen Infante-Duarte, Sven Jarius, Holger Jahn, Friedemann Paul, Klemens Ruprecht, Ana Luisa Pina
Pigment-epithelium derived factor (PEDF) is a neurotrophic factor with neuroprotective, anti-tumorigenic, and anti-angiogenic effects. Elevated levels of PEDF have previously been proposed as a cerebrospinal fluid (CSF) biomarker for Alzheimer's disease. However, the origin of PEDF in CSF, i.e. whether it is derived from the brain or from the systemic circulation, and the specificity of this finding hitherto remained unclear. Here, we analyzed levels of PEDF in paired CSF and serum samples by ELISA in patients with Alzheimer's disease (AD, n=12), frontotemporal dementia (FTD, n=6), vascular dementia (n=4), bacterial meningitis (n=8), multiple sclerosis (n=32), pseudotumor cerebri (n=36), and diverse non-inflammatory neurological diseases (n=19)...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28318059/low-normal-csf-a%C3%AE-42-levels-predict-clinical-progression-in-non-demented-subjects
#2
Betty M Tijms, Daniela Bertens, Rosalinde E Slot, Alida A Gouw, Charlotte E Teunissen, Philip Scheltens, Wiesje M van der Flier, Pieter Jelle Visser
We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid β 1-42 (≥640 pg/ml) levels related with rate of clinical progression in a sample of 393 non-demented memory clinic patients. Lower normal levels were associated with faster clinical progression and this depended on baseline cognitive status (subjective cognitive decline: HR = 0.59, p <.05; mild cognitive impairment: HR=0.12, p <.001), indicating that normal CSF amyloid levels do not exclude incident Alzheimer's disease. These findings suggest that research on preclinical markers for Alzheimer's disease should take the continuum of CSF amyloid β 1-42 levels within the normal range into account...
March 20, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28317649/clinical-validity-of-cerebrospinal-fluid-a%C3%AE-42-tau-and-phospho-tau-as-biomarkers-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#3
REVIEW
Niklas Mattsson, Anders Lönneborg, Marina Boccardi, Kaj Blennow, Oskar Hansson
Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28302766/csf-clearance-in-alzheimer-disease-measured-with-dynamic-pet
#4
Mony J de Leon, Yi Li, Nobuyuki Okamura, Wai H Tsui, Les A Saint Louis, Lidia Glodzik, Ricardo S Osorio, Juan Fortea, Tracy Butler, Elizabeth Pirraglia, Silvia Fossati, Hee-Jin Kim, Roxana O Carare, Maiken Nedergaard, Helene Benveniste, Henry Rusinek
Evidence supporting the hypothesis that reduced cerebrospinal fluid (CSF) clearance is involved in the pathophysiology of Alzheimer's disease (AD) comes from primarily from rodent models. However, unlike rodents where predominant extra-cranial CSF egress is via olfactory nerves traversing the cribriform plate, human CSF clearance pathways are not well characterized. Using dynamic Positron Emission Tomography (PET) with (18)F-THK5117 a tracer for tau pathology, the ventricular CSF time activity was used as a biomarker for CSF clearance...
March 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28293644/t-lymphocytes-and-inflammatory-mediators-in-the-interplay-between-brain-and-blood-in-alzheimer-s-disease-potential-pools-of-new-biomarkers
#5
REVIEW
Anna Mietelska-Porowska, Urszula Wojda
Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the main cause of dementia. The disease is among the leading medical concerns of the modern world, because only symptomatic therapies are available, and no reliable, easily accessible biomarkers exist for AD detection and monitoring. Therefore extensive research is conducted to elucidate the mechanisms of AD pathogenesis, which seems to be heterogeneous and multifactorial. Recently much attention has been given to the neuroinflammation and activation of glial cells in the AD brain...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28291839/microstructural-white-matter-alterations-in-preclinical-alzheimer-s-disease-detected-using-free-water-elimination-diffusion-tensor-imaging
#6
Andrew R Hoy, Martina Ly, Cynthia M Carlsson, Ozioma C Okonkwo, Henrik Zetterberg, Kaj Blennow, Mark A Sager, Sanjay Asthana, Sterling C Johnson, Andrew L Alexander, Barbara B Bendlin
Brain changes associated with Alzheimer's disease (AD) begin decades before disease diagnosis. While β-amyloid plaques and neurofibrillary tangles are defining features of AD, neuronal loss and synaptic pathology are closely related to the cognitive dysfunction. Brain imaging methods that are tuned to assess degeneration of myelinated nerve fibers in the brain (collectively called white matter) include diffusion tensor imaging (DTI) and related techniques, and are expected to shed light on disease-related loss of structural connectivity...
2017: PloS One
https://www.readbyqxmd.com/read/28290668/surface-assay-for-specific-detection-of-soluble-amyloid-oligomers-utilizing-pronucleon-peptides-instead-of-antibodies
#7
Evgenia G Matveeva, Jonathan R Moll, Mariam M Khan, Richard B Thompson, Richard O Cliff
Immunoassays such as enzyme-linked immunosorbent assays (ELISAs) are widely used for diagnostics; however, antibodies as detection reagents may be insufficiently selective and have other shortcomings. We present a novel non-antibody-based detection method based on binding target molecules to peptides (used as recognition molecules): a surface assay for A-β oligomers employing a peptide comprising amino acid residues of the human β-amyloid protein (Pronucleon peptide) as the capture agent. For the sake of convenience, we term this the "Pronucleon peptide-linked immunosorbent assay", or PLISA...
March 21, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28286328/two-distinct-classes-of-degenerative-change-are-independently-linked-to-clinical-progression-in-mild-cognitive-impairment
#8
Jean-Philippe Coutu, Emily R Lindemer, Ender Konukoglu, David H Salat
We previously demonstrated 2 statistically distinct factors of degeneration in Alzheimer's disease: one strongly related to white matter damage and age interpreted as "age- and vascular-related", and the other related to cortical atrophy thought to represent "neurodegenerative changes associated with Alzheimer's disease". Those factors are now replicated in a distinct cross-sectional data set of 364 participants from the Alzheimer's Disease Neuroimaging Initiative and their interpretation is improved using correlations with CSF biomarkers...
February 16, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28281838/diagnostic-function-of-the-neuroinflammatory-biomarker-ykl-40-in-alzheimer-s-disease-and-other-neurodegenerative-diseases
#9
Filippo Baldacci, Simone Lista, Enrica Cavedo, Ubaldo Bonuccelli, Harald Hampel
Neuroinflammation is a fundamental mechanism in the neurodegenerative diseases pathophysiology. Cerebrospinal fluid (CSF) YKL-40 - an indicator of microglial activation - has recently identified by proteomic studies as a candidate biomarker for Alzheimer's disease (AD). Areas covered: We review the impact of CSF YKL-40 as a pathophysiological biomarker for AD and other neurodegenerative diseases. CSF YKL-40 concentrations have been shown to predict progression from prodromal mild cognitive impairment to AD dementia...
March 10, 2017: Expert Review of Proteomics
https://www.readbyqxmd.com/read/28274759/insulin-deficiency-a-possible-link-between-obesity-and-cognitive-function
#10
Ghazaleh Nameni, Mahdieh Abbasalizad Farhangi, Ghazaleh Hajilouian, Parviz Shahabi, Mehran Mesgari Abbasi
BACKGROUND: Epidemiological studies proposed a linear connection between developing dementia including Alzheimer's disease (AD) and obesity. Adiposity, insulin resistance and dementia indicated probable mechanistic links in this process. Indeed, it has been known that optimum insulin action in the brain plays critical role in cognitive function; whereas, insulin resistance in obese individuals finally leads to insulin deficiency in central nervous system (CNS) and down regulation of the efficiency of insulin uptake from periphery into CSF...
March 6, 2017: International Journal of Developmental Neuroscience
https://www.readbyqxmd.com/read/28274265/reduced-cgmp-levels-in-csf-of-ad-patients-correlate-with-severity-of-dementia-and-current-depression
#11
Raphael Hesse, Ludwig Lausser, Pauline Gummert, Florian Schmid, Anke Wahler, Cathrin Schnack, Katja S Kroker, Markus Otto, Hayrettin Tumani, Hans A Kestler, Holger Rosenbrock, Christine A F von Arnim
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as depression. The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are essential second messengers that play a crucial role in memory processing as well as synaptic plasticity and are potential therapeutic targets...
March 9, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28269782/microrna-profile-in-patients-with-alzheimer-s-disease-analysis-of-mir-9-5p-and-mir-598-in-raw-and-exosome-enriched-cerebrospinal-fluid-samples
#12
Javier Riancho, José Luis Vázquez-Higuera, Ana Pozueta, Carmen Lage, Martha Kazimierczak, María Bravo, Miguel Calero, Andrea Gonalezález, Eloy Rodríguez, Alberto Lleó, Pascual Sánchez-Juan
BACKGROUND: MicroRNAs have been postulated as potential biomarkers for Alzheimer's disease (AD). Exosomes are nanovesicles which transport microRNAs, proteins, and other cargos. It has been hypothesized that the exosome traffic might be increased in neurodegenerative disorders. OBJECTIVE: i) To assess the cerebrospinal fluid (CSF) microRNA profile in a group of AD patients and control subjects and to validate a group of microRNAs previously reported by other authors...
February 25, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28269771/cerebrospinal-fluid-a%C3%AE-42-a%C3%AE-40-as-a-means-to-limiting-tube-and-storage-dependent-pre-analytical-variability-in-clinical-setting
#13
Christelle Gervaise-Henry, Gasshan Watfa, Eliane Albuisson, Allan Kolodziej, Brigitte Dousset, Jean-Luc Olivier, Thérèse Rivasseau Jonveaux, Catherine Malaplate-Armand
BACKGROUND: Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for AD diagnosis. Unfortunately, their wider use in routine and interpretation require more standardization, particularly for the pre-analytical steps. In particular, amyloid-β (Aβ)42 peptide measurement is strongly influenced by the type of collection tube and by repeated freeze/thaw cycles. OBJECTIVE: The objectives of this study were to compare, the in clinical setting, the impact of collection tubes and the repetition of freeze/thaw cycles on Aβ42 and Aβ40 concentrations and consequently determine if the Aβ42/Aβ40 ratio could resolve the diagnosis difficulties related to these pre-analytical parameters...
February 28, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28269767/effects-of-risperidone-and-galantamine-treatment-on-alzheimer-s-disease-biomarker-levels-in-cerebrospinal-fluid
#14
Victor Bloniecki, Dag Aarsland, Kaj Blennow, Jeffrey Cummings, Farshad Falahati, Bengt Winblad, Yvonne Freund-Levi
BACKGROUND: Treatment for neuropsychiatric symptoms (NPS) in dementia is insufficient. Antipsychotics and acetylcholinesterase inhibitors are used generating symptomatic improvements in behavior and cognition, but few studies have investigated their effect on Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF). OBJECTIVE: This is a secondary analysis based on an earlier clinical trial comparing the treatment effects on NPS. The aim of this study was to examine whether treatment with risperidone and galantamine affect levels of the biomarkers T-Tau, P-Tau, Aβ1-42, and Aβ42/40-ratio in CSF...
February 28, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28268812/identification-of-blood-biomarkers-for-use-in-point-of-care-diagnosis-tool-for-alzheimer-s-disease
#15
E Jammeh, P Zhao, C Carroll, S Pearson, E Ifeachor
Early diagnosis of Alzheimer's Disease (AD) is widely regarded as necessary to allow treatment to be started before irreversible damage to the brain occur and for patients to benefit from new therapies as they become available. Low-cost point-of-care (PoC) diagnostic tools that can be used to routinely diagnose AD in its early stage would facilitate this, but such tools require reliable and accurate biomarkers. However, traditional biomarkers for AD use invasive cerebrospinal fluid (CSF) analysis and/or expensive neuroimaging techniques together with neuropsychological assessments...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28263742/two-level-diagnostic-classification-using-cerebrospinal-fluid-ykl-40-in-alzheimer-s-disease
#16
Filippo Baldacci, Nicola Toschi, Simone Lista, Henrik Zetterberg, Kaj Blennow, Ingo Kilimann, Stefan Teipel, Enrica Cavedo, Antonio Melo Dos Santos, Stéphane Epelbaum, Foudil Lamari, Bruno Dubois, Roberto Floris, Francesco Garaci, Ubaldo Bonuccelli, Harald Hampel
INTRODUCTION: We assessed the diagnostic accuracy of cerebrospinal fluid (CSF) YKL-40 in discriminating (1) clinical Alzheimer's disease (AD) from cognitively healthy controls (HCs) and frontotemporal dementia (FTD) (level I) and (2) patients stratified by different pathophysiological profiles from HCs and FTD following a novel unbiased/descriptive categorization based on CSF biomarkers, independent of cognitive impairment severity (level II). METHODS: YKL-40 was compared among HCs (n = 21), mild cognitive impairment (n = 41), AD (n = 35), and FTD (n = 9) (level I) and among HCs (n = 21), AD pathophysiology (tau and amyloid-β) negative (n = 15), tau positive (n = 15), amyloid-β positive (n = 13), AD pathophysiology positive (n = 33), and FTD (n = 9) (level II)...
March 2, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28261965/relationship-between-cytokine-levels-in-the-cerebrospinal-fluid-and-11c-pittsburgh-compound%C3%A2-b-retention-in-patients-with-mild-cognitive-impairment
#17
Yoshitake Abe, Noriyuki Kimura, Ryuichi Takahashi, Megumi Gotou, Ken Mizukami, Hirotatsu Uchida, Etsuro Matsubara
AIM: In the present study, we examined the relationship between cytokine levels in the cerebrospinal fluid (CSF) and (11) C-Pittsburgh compound B (PiB) retention in patients with mild cognitive impairment. METHODS: A total of 33 participants (12 men and 21 women; mean age 76.5 years) with mild cognitive impairment underwent neuropsychological assessments, PiB positron emission tomography and analysis of cytokine levels in the CSF. The CSF levels of 48 cytokines and growth factors were measured using multiplex immunoassays...
March 5, 2017: Geriatrics & Gerontology International
https://www.readbyqxmd.com/read/28247064/genome-wide-association-study-identifies-four-novel-loci-associated-with-alzheimer-s-endophenotypes-and-disease-modifiers
#18
Yuetiva Deming, Zeran Li, Manav Kapoor, Oscar Harari, Jorge L Del-Aguila, Kathleen Black, David Carrell, Yefei Cai, Maria Victoria Fernandez, John Budde, Shengmei Ma, Benjamin Saef, Bill Howells, Kuan-Lin Huang, Sarah Bertelsen, Anne M Fagan, David M Holtzman, John C Morris, Sungeun Kim, Andrew J Saykin, Philip L De Jager, Marilyn Albert, Abhay Moghekar, Richard O'Brien, Matthias Riemenschneider, Ronald C Petersen, Kaj Blennow, Henrik Zetterberg, Lennart Minthon, Vivianna M Van Deerlin, Virginia Man-Yee Lee, Leslie M Shaw, John Q Trojanowski, Gerard Schellenberg, Jonathan L Haines, Richard Mayeux, Margaret A Pericak-Vance, Lindsay A Farrer, Elaine R Peskind, Ge Li, Antonio F Di Narzo, John S K Kauwe, Alison M Goate, Carlos Cruchaga
More than 20 genetic loci have been associated with risk for Alzheimer's disease (AD), but reported genome-wide significant loci do not account for all the estimated heritability and provide little information about underlying biological mechanisms. Genetic studies using intermediate quantitative traits such as biomarkers, or endophenotypes, benefit from increased statistical power to identify variants that may not pass the stringent multiple test correction in case-control studies. Endophenotypes also contain additional information helpful for identifying variants and genes associated with other aspects of disease, such as rate of progression or onset, and provide context to interpret the results from genome-wide association studies (GWAS)...
February 28, 2017: Acta Neuropathologica
https://www.readbyqxmd.com/read/28239639/alzheimer-s-biomarkers-in-daily-practice-abide-project-rationale-and-design
#19
Arno de Wilde, Ingrid S van Maurik, Marleen Kunneman, Femke Bouwman, Marissa Zwan, Eline A J Willemse, Geert Jan Biessels, Mirella Minkman, Ruth Pel, Niki S M Schoonenboom, Ellen M A Smets, Mike P Wattjes, Frederik Barkhof, Andrew Stephens, Erik J van Lier, Richard Batrla-Utermann, Philip Scheltens, Charlotte E Teunissen, Bart N M van Berckel, Wiesje M van der Flier
INTRODUCTION: The Alzheimer's biomarkers in daily practice (ABIDE) project is designed to translate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI). METHODS: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28239349/fear-and-uncertainty-do-not-influence-reported-willingness-to-undergo-lumbar-punctures-in-a-u-s-multi-cultural-cohort
#20
Dobromira Z Tsvetkova, Sharon H Bergquist, Monica W Parker, Thomas L Jarrett, Jennifer C Howell, Kelly D Watts, Alexander Kollhoff, David L Roberts, William T Hu
Cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease and related disorders can provide early and accurate prediction of underlying neuropathology even when the clinical symptoms are mild, but lumbar punctures (LP) to obtain CSF can be perceived as frightening and invasive. We previously demonstrated that this negative perception of the LP is strongly associated with a negative LP experience in terms of discomfort and complications, but it is not known what factors can lead to a negative perception of the LP...
2017: Frontiers in Aging Neuroscience
keyword
keyword
81816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"